The Quantitative Role Of The Kidneys In The In Viuo Metabolism Of Mevalonate

This 1977 study investigated how the body processes mevalonate, an important molecule that serves as a building block for cholesterol and other essential compounds. While the liver is typically considered the main site of cholesterol production, researchers wanted to understand what role the kidneys might play in this process.

The scientists used radioactive mevalonate in rats to track where and how this molecule gets processed throughout the body. They discovered that the kidneys are actually the primary site where circulating mevalonate gets converted into cholesterol and related compounds. About 74% of mevalonate follows the "sterol pathway" (making cholesterol), while 26% follows the "nonsterol pathway" for other uses. Remarkably, when they removed the kidneys from test animals, mevalonate processing dropped by about 60%, demonstrating the kidneys' central role.

The findings revealed that within 6 hours of mevalonate administration, the kidneys had converted most of it into cholesterol. However, the study also showed the body's remarkable adaptability - when kidneys were removed, other tissues could compensate and take over this cholesterol-making function, though less efficiently.

This research highlights an underappreciated aspect of kidney function beyond their well-known role in filtering waste. For metabolic health, it suggests that kidney health may be more interconnected with cholesterol metabolism than previously understood, though modern clinical practice focuses primarily on liver function for cholesterol management through diet, lifestyle, and medications when necessary.